Of note, it appears this patent is expiring elsewhere, including the largest markets in the world.

> The situation may not stop at Canada’s borders. “These issues are not unique to Canada. Similar waves of generic filings are expected or already underway in other countries where semaglutide patents are expiring, such as China, India, and Brazil,” explained Shape.

It's standard practice here to use the original title: "Did Novo open the Canadian market to GLP-1 generics?"

Patent, not patient!! :D